KRON - Kronos Bio streamlines leadership cuts CMOCSO and COO roles
2024-01-25 08:25:37 ET
More on Kronos Bio
- Kronos ends development of lanraplenib combo therapy for AML
- Kronos to cut 19% of workforce, focus on drugs KB-0742, lanraplenib
- Seeking Alpha’s Quant Rating on Kronos Bio
- Historical earnings data for Kronos Bio
- Financial information for Kronos Bio